Controlled study of brodimoprim and cephalexin in the treatment of patients with acute sinusitis in general practice.
Brodimoprim, a new dehydrofolate reductase inhibitor, was compared with cephalexin in the treatment of patients with acute sinusitis. A total of 49 patients were randomly assigned to receive either brodimoprim 200-mg tablets once a day (400 mg on the first day as a loading dose) or cephalexin 500-mg tablets three times a day for 8 to 12 days. Nearly all patients treated were judged clinically cured/improved; in fact, only one failure (in the cephalexin group) was noted. In the 45 assessable patients, the time until disappearance of the symptoms and the duration of treatment did not differ significantly between the two groups. A bacteriologic examination was performed in all patients at baseline as well as at the end of therapy. Bacteriologic eradication was obtained in 88% of the patients treated with brodimoprim and in 76% of those receiving cephalexin. Both compounds were generally well tolerated (one patient in the brodimoprim group complained of skin reactions). These results suggest that once-daily treatment with brodimoprim represents safe and effective therapy for adults with acute bacterial sinusitis.
Bockmeyer
M
M
ENT Department, Würzburg, Germany.
Riebenfeld
D
D
Clasen
B
B
D000208:Acute Disease; D000328:Adult; D000368:Aged; D002506:Cephalexin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005194:Family Practice; D005260:Female; D006094:Gram-Positive Bacteria / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D012449:Safety; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D014295:Trimethoprim / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014295:Trimethoprim; D002506:Cephalexin; C037079:brodimoprim